BJMO - 2022, issue SPECIAL, february 2022
A. Enguita PhD, T. Feys MBA, MSc
Next-Generation Sequencing (NGS) significantly changed cancer management, allowing the identification of different oncogenic drivers and the subsequent approval of many targeted agents. An overview of the Belgian reimbursement situation and drug access in this setting was given during the molecular tests in oncology session of the Belgian Society of Medical Oncology (BSMO) annual meeting. First, Prof. Brigitte Maes (Jessa Hospital, Hasselt) walked us through the current NGS situation in
Belgium with a discussion of the achievements and challenges of the BALLETT study. Subsequently, Dr. Kevin Punie (Leuven University Hospital, Leuven) discussed the current strategy, tasks and challenges of the molecular tumour board (MTB). Finally, Pr. Lore Decoster (University Hospital Brussel), Dr. Wim Demey (Klina General Hospital, Brasschaat) and Dr. Joëlle Collignon (CHU de Liège, Liège) addressed the reimbursements of drugs in lung, gastro-oesophageal, biliary and pancreatic cancer.
BJMO - 2022, issue SPECIAL, february 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
During the supportive care task force meeting, the BSMO supportive care task force introduced three clinical trials they would like to set up in the near future. In addition, new BSMO guidelines on extravasation and anaemia were presented after which the session was closed by Dr. Christel Fontaine (UZ Brussel) with a status update on the supportive care task force activities over the past year.
Read moreBJMO - 2022, issue SPECIAL, february 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
PACIFIC-R is a real-world international observational study evaluating patients with unresectable stage III non-small-cell-lung cancer treated with durvalumab following platinum-based chemoradiation. At the annual BSMO meeting, baseline characteristics and progression-free survival results for the Belgian cohort of this study were presented and contextualised with the PACIFIC-R global population and the durvalumab arm of the phase III PACIFIC trial.
Read moreBJMO - 2022, issue SPECIAL, february 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In this article selected studies influencing therapeutic guidelines in solid tumours, as well as highlights in breast cancer, lung cancer, digestive oncology, genitourinary cancer, biomarkers, and what’s new in rare tumours/histologies are discussed.
Read moreBJMO - 2022, issue SPECIAL, february 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
In the multidisciplinary oncology landscape, radiation oncology is becoming increasingly important in the treatment of many cancer patients. In this light, Prof. Dr. Liv Veldeman (University Hospital Ghent, Ghent, Belgium), president of the Belgian Society for Radiotherapy and Oncology (BeSTRO), discussed the most important steps in the radiotherapy process. In addition, she shared her experience with modern radiotherapy treatments and addressed how these innovative techniques may further
improve treatment outcomes.
BJMO - 2022, issue SPECIAL, february 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
With the increasing use of immunotherapy, more and more questions rise on the management of specific immune-related adverse events (irAEs) that are associated with these agents. Unfortunately, guidance on long-term irAE management is currently lacking and as patients with auto-immune disease or organ transplants were often excluded from clinical trials, there is also a lack of data on the use of immunotherapy in these setting. As irAEs can affect any organ system, it is not always easy to recognise and manage these adverse events in a timely manner, making multidisciplinary collaboration essential. To address these unmet needs, the Belgian Multidisciplinary Immunotoxicity Board was set up. During their talk at the BSMO annual meeting, Sandrine Aspeslagh, (MD, PhD, University Hospital Brussels, Brussels, Belgium) and Marthe Verhaert (MD, University Hospital Brussels, Brussels, Belgium) discussed the rationale, aim, and first results of this BITOX initiative.
Read moreBJMO - 2022, issue SPECIAL, february 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
Head and neck cancer (HNC) refers to a very heterogeneous group of tumours with different anatomic site, histology, and aetiology. The most common HNCs consist of squamous cell carcinomas of the pharynx, oral cavity, and larynx. As the selection of the best treatment option for patients with squamous cell carcinoma of the head can be difficult, Prof. Jean-Pascal Machiels (Cliniques Universitaires Saint-Luc, Brussels) gave an overview of the currently available and promising treatment combinations under investigation during a Keynote Lecture at the annual BSMO meeting.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
